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Abstract
Rationale—Reactive hyperemia (RH) in the forearm circulation is an important marker of
cardiovascular health yet the underlying vasodilator signaling pathways are controversial and thus
remain unclear.
Objective—We hypothesized RH occurs via activation of inwardly-rectifying potassium (KIR)
channels and Na+/K+-ATPase and is largely independent of the combined production of the
endothelial autocoidsnitric oxide (NO) and prostaglandins (PGs) in young healthy humans.
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Methods and Results—In 24 (23±1 years) subjects, we performed RH trials by measuring
forearm blood flow (FBF; venous occlusion plethysmography) following 5 minutes of arterial
occlusion. In Protocol 1, we studied 2 groups of 8 subjects and assessed RH in the following
conditions; Group 1:control (saline), KIR channel inhibition (barium chloride; BaCl2), combined
inhibition of KIR channels and Na+/K+-ATPase (BaCl2+ouabain, respectively), and combined
inhibition of KIR channels, Na+/K+-ATPase, NO and PGs (BaCl2+ouabain+L-NMMA+ketorolac,
respectively). Group 2 received ouabain rather than BaCl2 in the 2nd trial. In Protocol 2 (n=8), 3
RH trials were performed: control, L-NMMA+ketorolac, and L-NMMA+ketorolac
+BaCl2+ouabain. All infusions were intra-arterial (brachial). Compared to control, BaCl2
significantly reduced peak FBF (-50±6%; P<0.05) whereas ouabain and L-NMMA+ketorolac did
not. Total FBF (area under curve) was attenuated by BaCl2 (-61±3%) and ouabain (-44±12%)
alone and this effect was enhanced when combined (-87±4%), nearly abolishing RH. L-NMMA
+ketorolacdid not impact total RH FBF prior to or after administration of BaCl2+ouabain.
Conclusions—Activation of KIR channels is the primary determinant of peak RH, whereas
activation of both KIR channels and Na+/K+-ATPase explains nearly all of total RH in humans.
Keywords
Blood flow regulation; vasodilation; ischemia; hyperpolarization
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Following ischemia caused by temporary arterial occlusion, there is significant vasodilation
and a rapid marked increase in blood flow in most tissues, including the human forearm1.
This phenomenon of reactive hyperemia (RH) is thought to occur as a result of myogenic
and local metabolic or endothelial factors within the resistance vasculature and thus can be
used as a test of microvascular function3. Attenuated RH responses have been documented
in populations demonstrating a variety of risk factors that increase cardiovascular morbidity
and mortality including hypertension4-7, atherosclerosis8, peripheral artery disease9,
congestive heart failure10, and advanced age11. Recently, peak RH flow was determined to
be predictive of future cardiovascular events in a healthy population12 as well as in at-risk
patient populations13, and this predictive value may be greater than that of commonly
assessed macrovascular function via flow-mediated brachial artery vasodilation12, 14.
Despite the utility of the RH test as a measure of vascular health, the underlying
mechanisms of local vasodilation that contribute to this response in humans are largely
unknown.
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Given the strong associations between impaired RH, cardiovascular disease risk, and
attenuated endothelial-dependent and metabolic vasodilation15, 16, a variety of previous
investigations in humans have attempted to determine the role of numerous endothelialderived and metabolically-dependent substances or pathways involved in the response
including nitric oxide (NO)8, 17-20, prostaglandins (PGs)18, 21-23, ATP-dependent potassium
(KATP) channels17, 24 and adenosine22, 25, 26. The results of these studies are largely
equivocal and to date, even when the production or action of these substances are inhibited
in combination17, 18, 22, a significant portion of both the peak and total RH remains
unexplained. There is growing interest in vasodilation that occurs via non-NO and –PG
mechanisms due to hyperpolarization of endothelial and vascular smooth muscle cells27, 28.
Endothelial-derived hyperpolarization (EDH) can be broadly categorized into two groups:
“classical” EDH associated with activation of calcium-activated potassium channels (KCa)
and subsequent direct electrical communication or activation of inwardly-rectifying
potassium (KIR) channels and Na+/K+-ATPase resulting in hyperpolarization of vascular
smooth muscle cells and the second category of EDH, diffusible factors such as hydrogen
peroxide (H2O2) and the cytochrome-P450 metabolites [e.g. epoxyeicosatrienoic acid
(EET)]29. In this context, we recently demonstrated the ability to block the local
vasodilation to intra-arterial infusions of potassium chloride (KCl) via inhibition of KIR
channels and Na+/K+-ATPase in the human forearm, and further have shown that these
pathways can contribute to vasodilator responses to pharmacological stimulation of the
endothelium30 as well as increased metabolic demand31. Whether or not vascular
hyperpolarization via KIR channel and Na+/K+-ATPase activation contributes to RH in
humans has never been tested.
With this information as background, we directly tested the hypothesis that vascular
hyperpolarization via KIR channels and Na+/K+-ATPase contributes to forearm RH
following temporary arterial occlusion in healthy humans. Further, we sought to determine
whether combined inhibition of NO and PGs attenuates reactive hyperemia, as several
studies have demonstrated that individual inhibition of these endothelial pathways may not
impact hyperemic responses to a variety of physiological stimuli, whereas combined
inhibition can reveal a significant role in vascular control32, 33.
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A detailed and expanded Methods section is available in the online-only Supplemental
Materials.
Subjects
With Institutional Review Board approval and after written informed consent, a total of 24
young healthy adults [18 men, 6 women; age=23±1 years (range:18-34 years);
weight=73.1±1.5 kg; height=175±1 cm; body mass index=23.9±0.5 kg/m2; forearm volume
(FAV)=945±39 ml; means±s.e.m.] participated in the present study. All studies were
performed according to the Declaration of Helsinki.
Arterial catheterization, arterial blood pressure and heart rate
A 20 gauge, 7.6 cm catheter was placed in the brachial artery of the non-dominant arm
under aseptic conditions after local anesthesia (2% lidocaine) for local administration of
study drugs, blood sampling, and mean arterial pressure (MAP) measurement. Heart rate
(HR) was determined using a 3-lead electrocardiogram (Cardiocap/5, Datex-Ohmeda
Louisville, CO).
Forearm blood flow and vascular conductance
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Forearm blood flow (FBF) was measured via venous occlusion plethysmography using
mercury-in-silastic strain gauges and techniques as previously described30. FBF was
expressed as milliliters per deciliter of tissue per minute (ml/dl FAV/min). As an index of
forearm vasodilation and to account for individual differences in baseline vascular tone,
forearm vascular conductance (FVC) was calculated as (FBF/MAP) × 100 expressed as ml/
dl FAV/min/100mmHg. Immediately following the release of the occlusion cuff for the RH
(see below), the same cuffcycled between inflation at ∼50 mmHg (4 seconds) and deflation
(3 seconds) to cause venous occlusion and this yielded one blood flow measurement every 7
seconds for the first 56 seconds (8 flow measures). After 8 flow measures, the
inflation:deflation cycle was changed back to 7:8 seconds, as was used at rest.
RH protocol
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After measurement of baseline FBF, the cuff on the upper arm was rapidly inflated to 200
mmHg for 5 minutes of ischemia. This location and duration of ischemia was chosen to
mimic the RH protocol utilized in investigations of the contributions of various endothelialderived vasodilator pathways to the RH response18, 19, 22, 23 and importantly, has recently
demonstrated peak RH flow to be more strongly associated with cardiovascular disease risk
than measures of flow-mediated vasodilation12. After 5 minutes, the cuff was rapidly
deflated and flow measures commenced for 2.5 minutes (150 seconds). To determine the
effect of repeated bouts of RH, 8 additional young subjects were instrumented noninvasively and underwent four successive bouts of RH separated by 20 minutes of rest (see
Online Supplemental Materials for details).
Vasoactive drug infusion
All drug infusions were through the brachial artery catheter to create a local effect in the
forearm, we recompleted during baseline measures prior to the arterial occlusion, and saline
was utilized as a control infusate. Specific timing and duration of infusions is provided
below in the Experimental Protocols section.
To inhibit KIR channels, barium chloride (BaCl2; KIR channel inhibitor; 10% w/v
BDH3238, EMD Chemicals, Gibbstown, NJ) was infused at 0.9 μmol/dl FAV/min within an
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absolute range of 8 μmol/min to 10 μmol/min for five minutes prior to each arterial
occlusion. To inhibit Na+/K+-ATPase, ouabain octahydrate (Na+/K+-ATPase inhibitor;
Sigma 03125, St. Louis, MO) was infused at 2.7 nmol/min for 15 minutes prior to arterial
occlusion30, 34. On subsequent RH trials, ouabain was reinfused for 5 minutes prior to
arterial occlusion to provide continuous inhibition. This approach of using BaCl2 and
ouabain to inhibit KIR channels and Na+/K+-ATPase, respectively, has been used previously
by our group30, 35 and others36, 37. We administered NG-monomethyl-l-arginine (l-NMMA;
NO synthase inhibitor; Clinalfa/Bachem, Weil am Rhein, Germany) to inhibit the production
of NO in combination with ketorolac (non-selective cyclooxygenase inhibitor; Hospira,
Lake Forest, IL) to inhibit the synthesis of PGs. The doses of l-NMMA and ketorolac were 5
mg/min and 1200 μg/min respectively and given for 5 minutes30 prior to arterial occlusion.
Experimental protocols
In all experimental protocols, subjects rested quietly for 30 minutes after insertion of the
catheter before the first experimental trial and for 20 minutes between each RH trial.
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Protocol 1: Independent and combined effects of KIR channel and Na+/K+ATPase inhibition—This protocol was designed to primarily address the role of KIR
channels and Na+/K+-ATPase in the RH response. In total, 16 subjects participated in this
protocol. Eight of these subjects (Group 1) underwent RH trials in the following conditions:
(1) control (saline), (2) independent KIR channel inhibition (BaCl2), (3) combined KIR
channel and Na+/K+-ATPase inhibition (BaCl2+ouabain), and (4) inhibition of KIR
channels, Na+/K+-ATPase, as well as NO and PGs (BaCl2+ ouabain+L-NMMA+ketorolac).
In the other eight subjects (Group 2), the protocol was the same except that the second trial
consisted of independent inhibition of Na+/K+-ATPase via ouabain versus BaCl2 infusion.
Protocol 2: Effects of combined inhibition of NO and PGs—To further address the
combined role of NO and PGs in RH and assess the role of KIR channel and Na+/K+-ATPase
activation, we performed a second protocol (n=8) that consisted of RH trials in the following
conditions: (1) control (saline), (2) combined NO and PG inhibition (L-NMMA+ketorolac),
and (3) inhibition of the production of NO and PGs as well as KIR channels and Na+/K+ATPase (L-NMMA+ketorolac+BaCl2+ouabain).
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Protocol 3: Control vasodilator stimulus—In a subset of subjects (n=6), sodium
nitroprusside (SNP; Nitropress, Hospira Inc., Lake Forest, IL) was infused at 2 μg/dl FAV/
min for 5 minutes38 in control (saline) conditions and after prior administration of all four
antagonists (BaCl2+ouabain+L-NMMA+ketorolac) as a negative control to confirm intact
capacity of the forearm resistance vasculature to vasodilate.
Data acquisition and analysis
Data were collected and stored on a computer at 250 Hz and were analyzed off-line with
signal-processing software (WinDaq, DATAQ Instruments, Akron, OH). MAP was
determined from the arterial pressure waveform. FBF was determined from the derivative of
the forearm plethysmography signal. For resting hemodynamic measures, the average of the
last minute of baseline was used. To quantify the RH response, we averaged and plotted
values from each subject at all FBF time points (7, 14, 21, 28, 35, 42, 49, 56, 60, 75, 90,
105, 120, 135, 150 seconds post-cessation of arterial occlusion) and the total reactive
hyperemic FBF [area under the curve (AUC)] was determined as the sum of FBF above
baseline at each time point. The peak RH FBF and vasodilation (FVC) was determined for
each subject individually and these values were also averaged. In all subjects, these
individual peaks occurred at either the first, second, or third flow measurements. When FBF/
FVC measurements for all subjects were averaged at each time point, the peak nearly always
Circ Res. Author manuscript; available in PMC 2014 September 27.
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occurred at the first flow measurement (see Results). To quantify the impact of the
vasoactive inhibitors, the magnitude of inhibition (%Δ) was calculated as: (FBFpeak/total
inhibition – FBFpeak/total control)/(FBFpeak/total control)×100 and always quantified from the
control condition. For the SNP control trials, FBF was averaged across the last minute of
baseline and SNP infusion.
Statistics
Data are presented as mean±s.e.m. Dynamic post-occlusion FBF values were analyzed via
two-way repeated measures ANOVA (time × condition). To make comparisons of peak and
total RH FBF and baseline hemodynamics between each of the experimental conditions
within a given protocol, we used one-way repeated measures ANOVA. For comparisons
between protocols, a one-way ANOVA was utilized. In all cases, Student-Newman-Keuls
post hoc pairwise comparisons were made when a significant F was observed. Significance
was set a priori at P<0.05.

Results
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No significant differences in subject characteristics were detected between the 3
experimental groups. Baseline systemic hemodynamics (HR, MAP) and FBF for all
experimental protocols are presented in Table 1 and baseline FVC values are presented in
Table 2. For all protocols, there were no significant changes in HR or MAP during or
following the 5 minutes of arterial occlusion (data not shown).
Protocol 1: Independent and combined effects of KIR channel and Na+/K+-ATPase
inhibition
In Group 1 of Protocol 1, subjects received BaCl2 alone following the control trial in order
to assess the independent role of KIR channels in RH. A representative tracing of one subject
who participated in this protocol is provided in Figure 1 in control conditions (Panel A) and
following BaCl2 infusion (Panel B). Baseline FBF and FVC are presented in Tables 1 and 2.
During RH, BaCl2 significantly reduced the peak response (-50±6%; Figure 2A and B) and
impaired FBF for the first 75 seconds (Figure 2A). Taken together, the total RH FBF was
also significantly reduced from control levels (-62±3%; Figure 2C). The addition of ouabain
did not further impact peak RH FBF (-60±7%; BaCl2 vs BaCl2+ouabain; P=0.25) but there
was a strong trend towards an additional effect on total RH FBF (-82±4%; P=0.07). The
addition of L-NMMA+ketorolac did not have a further impact (Peak: -68±7%; Total:
-88±3%). Changes in peak vasodilation (FVC) paralleled those of FBF (Table 2).
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In Group 2 of Protocol 1, subjects received ouabain alone following the control trial in order
to assess the independent role of Na+/K+-ATPase in RH (Figure 3). Ouabain had no effect
on peak RH FBF (2±6%; Figure 3A and B) but did significantly reduce FBF during 14-90
seconds of hyperemia, resulting in a significant attenuation of the total RH FBF (-44 ±12%;
Figure 3C). The addition of BaCl2 significantly reduced peak RH FBF (-62±8%) as well as
further reduced total RH FBF (-92±8%) whereas there was no additional effect of L-NMMA
+ketorolac on either peak (-63±7%) or total RH FBF (-94±8%). Changes in peak
vasodilation (FVC) paralleled those for FBF (Table 2).
Protocol 2: Effects of combined inhibition of NO and PGs
In Protocol 2, we assessed the combined contribution of NO and PGs to RH and
subsequently inhibited KIR channels and Na+/K+-ATPase (Figure 4). As would be expected
with effective inhibition, L-NMMA+ketorolac significantly reduced baseline FBF and FVC
(Tables 1-3). The mean of the first FBF measures was augmented with L-NMMA+ketorolac
(Figure 4A); however, when each individual subjects' peak response was averaged, this
Circ Res. Author manuscript; available in PMC 2014 September 27.

Crecelius et al.

Page 6

NIH-PA Author Manuscript

comparison only approached being significant (+18±8%; P=0.07; Figure 4B). FBF was
attenuated with L-NMMA+ketorolac 30-60 seconds following the end of arterial occlusion
(Figure 4A), yet the total RH FBF remained similar to control (-10±12%; P=0.24; Figure
4C). The additional inhibition of KIR channels and Na+/K+-ATPase via BaCl2 and ouabain,
respectively, significantly attenuated both peak (-61±8%; Figures 4A and B) and total
(-69±6%; Figure 4C) RH FBF.
Comparison of RH protocols
A summary of the relative (%Δ) effects of independent and combined roles of KIR channels
and Na+/K+-ATPase, as well as combined NO and PGs as compared to control conditions is
presented in Figure 5. In these pooled comparisons (BaCl2: n=8; ouabain: n=8;
BaCl2+ouabain: n=16; L-NMMA+ketorolac: n=8; BaCl2+ouabain+L-NMMA+ketorolac:
n=24) the reduction of peak FBF from BaCl2 alone (-50±6%) to combined BaCl2+ouabain
(-61±6%) was similar (P=0.15). Total RH FBF was attenuated by BaCl2 alone (-62±3%)
and ouabain alone (-44±12%) and this effect was enhanced when these inhibitors were
combined (-87±4%), nearly eliminating the hyperemic response to ischemia. L-NMMA
+ketorolachad no independent effects on peak (P=0.68) or total RH FBF (P=0.69) nor did
they enhance any inhibition beyond that which occurred with BaCl2+ouabain infusion
(Peak: -64±4%; P=0.60; AUC:-84±4%; P=0.62).
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Protocol 3: Control vasodilator stimulus
Given the profound effects of our inhibitors on total RH, we wanted to confirm preserved
vasodilator capacity after administration of BaCl2+ouabain+L-NMMA+ketorolac. To do so,
SNP was administered in control (saline) conditions and at the end of the experimental
protocol in a subgroup of 6 subjects. Baseline FBF and FVC were reduced following
infusion of BaCl2+ouabain+L-NMMA+ketorolac, however there was no significant
reduction in the absolute level, absolute change, or relative change in FBF and FVC during
SNP infusion (Table 3).

Discussion
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The primary novel finding from the current study is that activation of KIR channels and Na+/
K+-ATPase and presumed subsequent vascular hyperpolarization explains nearly 90% of the
total RH response to temporary ischemia, whereas NO and PGs have no significant
combined role in this response (Figure 5). KIR channels appear to be involved in both the
peak and total FBF response; however, Na+/K+-ATPase only contributes to the total RH
FBF and not the peak FBF. The present findings lend novel and significant mechanistic
insight into this basic microvascular response that has been shown to have clinical relevance
in a variety of conditions that increase cardiovascular disease morbidity and mortality.
Historical overview of RH in humans
Beginning with the initial observation nearly 70 years ago of a rapid and profound
hyperemia in response to a period of ischemia, there was interest in determining the
underlying signals for this response1, 2, 7, 20, 23. Early experiments determined that an intact
nervous system was not requisite to observe this response2, 10 and subsequent studies
pursued investigating local mechanisms of vascular control that might be
involved8, 17-20, 22, 24. Alongside these studies aimed to determine the physiological basis of
RH, the test itself began to be used as a measure of vascular health in a variety of at-risk
populations4-7, 9, 10. Different groups of subjects that demonstrated “endothelial
dysfunction” as commonly assessed by intra-arterial infusion of endothelium-dependent
vasodilators (e.g. acetylcholine) or flow-mediated vasodilation of the brachial artery were
shown to have attenuated RH responses4-7, 9, 10. These associations among cardiovascular
Circ Res. Author manuscript; available in PMC 2014 September 27.
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disease, endothelial health, and impaired RH have further stimulated an interest in the
potential underlying mechanisms of this response. Importantly, recent evidence indicates
that peak RH flow in response to five minutes of ischemia (via upper arm cuff inflation)
may in fact be a better predictor of cardiovascular events than the more commonly-assessed
brachial flow-mediated vasodilation12. Thus, elucidating the mechanisms underlying this
physiological response has clear significant clinical implications.
Several potential mediators and downstream targets underlying RH have been postulated
and experimentally tested in both humans and experimental animals. Due to the ischemic
nature of the stimulus, classic metabolic candidates for regulating RH include adenosine or
KATP channel activation. Augmenting adenosine signaling through caffeine (adenosine
receptor antagonist) withdrawal or dipyridamole (inhibitor of cellular uptake of adenosine)
does improve RH; however, direct inhibition of adenosine receptors (via theophylline or
caffeine) does not impair peak RH FBF22, 26 and has a minimal effect on total FBF22.
Similarly, results from inhibition of KATP channels have been equally as unsuccessful in
explaining RH. Inhibition of KATP channels via sulfonylureas such as tolbutamide or
glibenclamide modestly reduces total RH FBF but has no impact on the peak response in
some studies17, 24, whereas other investigators have demonstrated no effect of KATP channel
inhibition on either peak or total RH 39.

NIH-PA Author Manuscript

Endothelium-derived NO and PGs contribute little to RH in humans
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It is well known that endothelial-derived NO contributes to cardiovascular health in humans
due to its multifaceted cardioprotective properties27. Whether NO mediates RH was a
logical proposition and has been investigated in a variety of existing studies8, 17-20. There is
discrepancy within the literature, and our present finding that NO (in combination with PGs)
does not contribute to peak RH FBF fits with the results of most5, 20, 36, 40 but not all8, 41 of
these studies. Some of the previous work has shown a modest role for NO in the total
hyperemic response17, 18, 20. Additionally, previous studies demonstrated only a minimal
contribution of endothelial-derived PGs to peak and/or total RH18, 21, 22. However, it is
important to note that significant cross-talk occurs between these two endothelial pathways,
such that inhibition of one pathway often does not impact vascular responses to a variety of
stimuli, whereas combined inhibition reveals a significant role32, 33. Only one study to date
inhibited NO and PGs in combination, and this was done with intra-arterial L-NMMA and
oral ibuprofen18. In this prior study, there was no impact on the peak change in FBF in
response to ischemia, whereas there was some reduction (∼35%) in the prolonged
hyperemic response18. Our current findings agree with these observations that even in
combination, NO and PGs do not contribute to peak RH FBF, and while we observed a
reduction in absolute FBF in the latter portion of RH, this was not of sufficient magnitude to
impair the total RH FBF (Figure 4). An interesting observation in the present study was that
peak RH was somewhat augmented after combined NO and PG inhibition, and this could
also reflect a critical role for vascular hyperpolarization in the response as NO is capable of
suppressing EDH-mediated vasodilation42. Although presently unclear, another explanation
for this augmented response is our inhibition of cyclooxygenase may have shifted
arachadonic acid to the cytochrome p450 pathway, thus increasing the production of EETs
to cause additional vasodilation27.
Critical role for KIR channel and Na+/K+-ATPase activation in RH in humans
Based on our assessment in the present study, there is a prominent role for KIR channels and
Na+/K+-ATPase in RH in humans (Figure 5). Interestingly, only KIR channel activation, but
not Na+/K+-ATPase contributed to the peak RH FBF. Selective inhibition of KIR channels
reduced the peak hyperemic response ∼50%, and a total of ∼60% was observed when
inhibition of Na+/K+-ATPase was performed simultaneously. Inhibition of KIR channels and
Circ Res. Author manuscript; available in PMC 2014 September 27.
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Na+/K+-ATPase independently reduced the total RH FBF by ∼60% and ∼40% respectively,
and this effect is enhanced when these are inhibited in combination. In this context, there is
a remarkable reduction in the total response (-87±4%) from control, nearly abolishing RH.
Collectively, the magnitude of the observed attenuation due to KIR channel inhibition on
peak hyperemia, and combined KIR and Na+/K+-ATPase inhibition on the total hyperemic
response, is by far the greatest in the known studies to date on this topic.
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Endothelium-dependent vasodilation that occurs beyond NO and PGs causes
hyperpolarization of endothelial cells and vascular smooth muscle cells27. “Classic' EDH is
sensitive to inhibition of KCa channels that when activated cause hyperpolarization of
endothelial and smooth muscle cells through direct electrical communication or stimulation
of KIR channels and Na+/K+-ATPase29. Our findings of a significant role for KIR channel
and Na+/K+-ATPase activation in RH in humans is consistent with the classic proposed
mechanism of EDH. However, we must also recognize that the RH response may be
endothelium-independent, yet still occur through vascular smooth muscle cell
hyperpolarization28. Recently, KIR channels have been shown to be particularly important
for the amplification of hyperpolarizing stimuli as they are directly responsive to changes in
membrane potential43 and thus, this unique property may explain the profound impact of
BaCl2 administration we observe on both peak and total reactive hyperemia. We are not able
to address cell-specific issues related to the KIR and Na+/K+-ATPase activation that we
observe in the present study due to the limitations of our human in vivo model.
Experimental considerations
All of the inhibitors utilized were administered prior to arterial occlusion and RH. This may
lead one to question the efficacy of our inhibitors after the 5 minutes of occlusion and
subsequent large increases in blood flow. While not directly assessed, we used doses
previously established in our laboratory30 and given the large magnitude of the effects on
peak and total RH FBF we observed, do not think this consideration affects our primary
conclusions. If anything, we maybe potentially underestimating a role for KIR channels and
Na+/K+-ATPase in RH. Further, we show that RH responses are largely repeatable over
time, with only a slight decline (-9±5%) in peak RH in the 4th trial as compared to the 1st
trial (see Supplemental Figure I) and no change in AUC. Thus, the marked impact of BaCl2
and ouabain we observe cannot be attributed to reduced responses with repeated trials.
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BaCl2 has been demonstrated to be primarily selective for KIR channels up to a
concentration of 100 μmol/L44. Dawes and colleagues demonstrated that a dose at half of
what we used increased antecubital venous plasma concentrations in the infused forearm to
50 μmol/L36 and thus, it can be assumed that our dose would result in concentrations within
the selective range for KIR channels. A direct assessment of the selectivity of BaCl2 for KIR
channels is difficult in humans as it is not possible to make membrane potential
measurements or isolate selective stimulation of this channel. Along these lines, at greater
concentrations, BaCl2 has been shown to inhibit other potassium channels, most
prominently KATP channels. While we believe that BaCl2 in the dose we administered is
selective for KIR channels, if we are in fact inhibiting KATP channels, this likely does not
provide an alternate explanation for our findings as the majority of existing data shows littleto-no impact of inhibiting KATP channels on peak and/or total RH 17, 24, 39. Further, our
group30, 31, 35 and others36, 37 have demonstrated that each of the pharmacological inhibitors
we use in this investigation do not impact overall vascular responsiveness nor have systemic
effects in the doses utilized.
Presently, the exact stimulus for vascular hyperpolarization in response to local ischemia is
unknown. Potential candidates include substances that have been shown to cause
vasodilation through KIR channels and/or Na+/K+-ATPase such as K+30, 45, ATP30,
Circ Res. Author manuscript; available in PMC 2014 September 27.
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bradykinin37, H2O246, and EETs47 and it is possible that concentrations of these substances
may rise during ischemia as has been observed in animal models, particularly in the
coronary circulation48. However, to the best of our knowledge, limited studies in humans
have made interstitial measures of the candidate substances during ischemia in skeletal
muscle, and to date, no significant increases have been observed49. Alternatively, evidence
suggests that mechanosensitive mechanisms such as the myogenic response and stretch of
endothelial cells contribute to the earliest portion of RH40. In this context, recent data
indicate that low intravascular pressure can stimulate transient receptor potential channels
that elicit changes in endothelial cell calcium which can stimulate vasodilation via
hyperpolarization50 and this might also serve as a stimulus for KIR channel and/or Na+/K+ATPase activation. Identifying the stimulus for KIR channel and Na+/K+-ATPase activation
that occurs during RH represents an intriguing future area of research and potentially would
provide valuable insight into explaining impaired RH responses in clinical populations.
Conclusions
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Following temporary arterial occlusion, there is a significant increase in blood flow in the
forearm vasculature of humans, the magnitude of which reflects microvascular function and
is an important marker of overall vascular health and future cardiovascular disease risk.
Here, we show that the majority of this response, in terms of both the initial peak hyperemia
as well as the total hyperemia above baseline that occurs throughout the duration of the
response depends on activation of KIR channels and Na+/K+-ATPase. Additionally, our
findings support the previous investigations that showed little-to- no role for NO and PGs in
RH in humans, despite associations between RH and endothelial function4-13. Given the
strong relation between attenuated RH responses and cardiovascular disease morbidity and
mortality12, and as a result of this study, RH and vascular hyperpolarization via KIR
channels and Na+/K+-ATPase, these vasodilator pathways present an exciting future
direction for studies in patient populations and suggest that “vascular health” may extend
beyond the commonly-assessed NO bioavailability. Moreover, these findings could be
particularly important for populations that exhibit microvascular dysfunction and may serve
as a target for specific therapies to improve microvascular blood flow control in humans.
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AUC

area under curve

BaCl2

barium chloride

EDH

endothelial-derived hyperpolarization

EET

epoxyeicosatrienoic acid

FAV

forearm volume

FBF

forearm blood flow

FVC

forearm vascular conductance

HR

heart rate

H2O2

hydrogen peroxide

KATP

ATP-dependent potassium channel

KCa

calcium-activated potassium channel

KIR

inwardly-rectifying potassium channel

l-NMMA

NG-monomethyl-l-arginine

MAP

mean arterial pressure

NO

nitric oxide

PGs

prostaglandins
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RH

reactive hyperemia

SNP

sodium nitroprusside
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What Is Known?
•

Reactive hyperemia (RH) describes the rapid, large increase in blood flow that
occurs in response to a brief circulatory occlusion.

•

Impaired reactive hyperemic responses are associated with increased
cardiovascular disease risk, yet the underlying mechanisms of RH in humans are
not clear.

What New Information Does This Article Contribute?
•

In young healthy humans, activation of inwardly-rectifying potassium (KIR)
channels contributes substantially to both peak and total (area under the curve)
RH measured by changes in forearm blood flow.

•

Activation of Na+/K+-ATPase contributes to total RH but not peak RH in the
forearm.

•

There is no combined role of nitric oxide (NO) and prostaglandins (PGs) to
either peak or total RH in the forearm.
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Despite the use of RH as a test of vascular function and as a marker of cardiovascular
disease risk, the underlying signaling mechanisms that contribute to this response remain
unclear. To date, inhibition of vasodilator substances such as NO and PGs, have not been
able to explain RH. Activation of KIR channels and Na+/K+-ATPase can lead to vascular
hyperpolarization and vasodilation, however; these signaling pathways have not been
studied with respect to RH. In young healthy humans, we demonstrate that intra-arterial
inhibition of KIR channels reduces both peak (∼50%) and total (∼60%) RH in the human
forearm. Activation of both KIR channels and Na+/K+-ATPase explains nearly all
(∼90%) of the total RH response. Our findings now provide important connections
among vascular hyperpolarization, RH and cardiovascular disease risk and may have
significant implications for patient populations that demonstrate impaired microvascular
function.
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Figure 1. Representative Tracing of Baseline and Reactive Hyperemia

Representative tracing (n=1) of the last 30 seconds of rest and the first minute of the reactive
hyperemia response in control (saline; A) conditions and with inhibition of KIR channels via
BaCl2 (B). Tracings are shown for the electrocardiogram (ECG), intra-arterial pressure (I.A.
Press.), and venous occlusion plethysmography (VOP) output from which heart rate, mean
arterial pressure, and forearm blood flow, respectively, are calculated and/or derived. Notes:
The vertical scale for VOP is 4 times greater during rest (pre-occlusion) than during reactive
hyperemia (post-occlusion). Vertical deflections indicate balancing of the plethysmography
signal to maintain a consistent baseline.
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Figure 2. Protocol 1: Independent effects of KIRchannel inhibition (Group 1)
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A. Forearm blood flow (FBF) response following 5 minutes of arterial occlusion in the
following conditions: control (black circles), independent KIR channel inhibition (BaCl2;
dark grey triangles), combined KIR channel and Na+/K+-ATPase inhibition (BaCl2+ouabain;
light grey squares), and combined inhibition of KIR channels, Na+/K+-ATPase, NO and PGs
(BaCl2+ouabain+L-NMMA+ketorolac; white diamonds) conditions. BaCl2 significantly
inhibited the response for 75 seconds and there was little additional effect of ouabain, or LNMMA+ketorolac. *P<0.05 vs BaCl2; †P<0.05 vs BaCl2+ouabain; ‡ P<0.05 vs
BaCl2+ouabain+L-NMMA+ketorolac. B. Peak reactive hyperemic FBF was significantly
attenuated from control by BaCl2, and ouabain had no additional effect whereas there was a
slightly greater reduction with the addition of L-NMMA+ketorolac. *P<0.05 vs Control;
†P<0.05 vs BaCl2. C. Similarly, total reactive hyperemic FBF (area under curve) was
significantly reduced from control by BaCl2, and ouabain had no additional effect whereas
L-NMMA+ketorolac further reduced this response. *P<0.05 vs Control; †P<0.05 vs BaCl2.
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Figure 3. Protocol 1: Independent effects of Na+/K+-ATPase inhibition (Group 2)
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A. Forearm blood flow (FBF) response following 5 minutes of arterial occlusion in control
(black circles), independent Na+/K+-ATPase inhibition (Ouabain; dark grey triangles),
combined Na+/K+-ATPase and KIR channel inhibition (Ouabain+BaCl2; light grey squares),
and combined inhibition of Na+/K+-ATPase, KIR channels, NO and PGs (Ouabain
+BaCl2+L-NMMA+ketorolac; white diamonds) conditions. Ouabain did not affect initial
FBF, but thereafter reduced FBF from control until 90 seconds post-cuff deflation. The
addition of BaCl2 further attenuated FBF for 30 seconds, whereas addition of L-NMMA
+ketorolac had no further effect. *P<0.05 vs Ouabain; †P<0.05 vs Ouabain+BaCl2; ‡P<0.05
vs Ouabain+BaCl2+L-NMMA+ketorolac. B. Peak reactive hyperemic FBF was not affected
by ouabain. Infusion of BaCl2 significantly reduced peak FBF from control, and L-NMMA
+ketorolac had no further impact. *P<0.05 vs Control; †P<0.05 vs Ouabain. C. Total
reactive hyperemic FBF (area under curve) was significantly reduced from control by
ouabain, and BaCl2 had an additional effect whereas L-NMMA+ketorolac did not. *P<0.05
vs Control; †P<0.05 vs Ouabain.
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Figure 4. Protocol 2: Effects of combined inhibition of nitric oxide and prostaglandins
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A. Forearm blood flow (FBF) response following 5 minutes of arterial occlusion in control
(black circles), combined inhibition of NO and PG synthesis (L-NMMA+ketorolac; light
grey squares), and combined inhibition of NO, PGs, KIR channels and Na+/K+-ATPase (LNMMA+ketorolac +BaCl2+ouabain; white diamonds) conditions. L-NMMA+ketorolac
attenuated the response from control only from 30-60 seconds post-cuff deflation. The
addition of BaCl2+ouabain significantly reduced FBF for 30 seconds and thereafter had no
further effect. *P<0.05 vs L-NMMA+ketorolac; †P<0.05 vs L-NMMA+ketorolac
+BaCl2+ouabain. B. Peak reactive hyperemic FBF was not affected by L-NMMA+ketorolac
and was significantly attenuated by L-NMMA+ketorolac +BaCl2+ouabain. *P<0.05 vs
Control; †P<0.05 vs L-NMMA+ketorolac. C. Similar to peak, total reactive hyperemic FBF
(area under curve) was not affected by L-NMMA+ketorolac and was significantly attenuated
by L-NMMA+ketorolac +BaCl2+ouabain. *P<0.05 vs Control; †P<0.05 vs L-NMMA
+ketorolac.
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Figure 5. Summary: Effects of inhibition of KIRchannels, Na+/K+-ATPase, nitric oxide and
prostaglandins on peak and total reactive hyperemia
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Combined results from the three experimental protocols are presented for relative impact
(%Δ) on both peak (A) and total (B) reactive hyperemic forearm blood flow (FBF) in each
experimental condition (BaCl2: n=8; Ouabain: n=8; BaCl2+ouabain: n=16; L-NMMA
+ketorolac: n=8; BaCl2+ouabain+L-NMMA+ketorolac: n=24). BaCl2 reduced peak FBF
and this attenuation was unchanged with the addition of ouabain or L-NMMA+ketorolac.
Neither ouabain alone nor L-NMMA+ketorolac attenuated peak FBF. BaCl2 and ouabain
both independently reduced total FBF and in combination (BaCl2+ouabain), the reduction
was enhanced. There was no additional reduction by L-NMMA+ketorolac, nor did LNMMA+ketorolac independently reduce total FBF. *P<0.05 vs zero; †P<0.05 vs BaCl2;
‡P<0.05 vs Ouabain
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*

n=6;

10.1±2.0

1.5±0.3*

SNP 2 μg/dl FAV/min

15.3±2.1

12.4±1.5

SNP 2 μg/dl FAV/min

FBF

Baseline

2.5±0.4

FVC

BaCl2+ouabain +L-NMMA+ketorolac

2.2±0.3

Baseline

FBF

Control (saline)

NIH-PA Author Manuscript
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Protocol 3: Control vasodilator stimulus
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